Castle Biosciences Inc (CSTL)
27.50
-0.01
(-0.04%)
USD |
NASDAQ |
Dec 23, 16:00
27.50
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 770.20M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 34.33% |
| Valuation | |
| PE Ratio | 130.95 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.483 |
| Price to Book Value | 1.746 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0227 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 88.02% |
Profile
| Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. |
| URL | https://www.castlebiosciences.com |
| Investor Relations URL | https://ir.castlebiosciences.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 28, 2025 (est.) |
| Last Earnings Release | Nov. 04, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. |
| URL | https://www.castlebiosciences.com |
| Investor Relations URL | https://ir.castlebiosciences.com/ |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Health Care Providers & Services |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Feb. 28, 2025 (est.) |
| Last Earnings Release | Nov. 04, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |